ReviewInfectious disorders drug targets2012
Targeting RSV with vaccines and small molecule drugs.
Review in Infectious disorders drug targets, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 36 citations in OpenAlex.
- Discovery of potential RSV fusion protein inhibitors from benzimidazole derivatives using QSAR, molecular docking, and ADMET evaluation methods.Molecular diversity · 2026Article
- RSV vaccine development: advances and fusion protein-focused strategies.Frontiers in immunology · 2026Review
- Potentiality of bioactive compounds as inhibitor of M protein and F protein function of human respiratory syncytial virus.In silico pharmacology · 2024Article
- Synthesis and evaluation of 3-alkynyl-5-aryl-7-aza-indoles as broad-spectrum antiviral agents.Frontiers in chemistry · 2022Article
- Respiratory syncytial virus entry and how to block it.Nature reviews. Microbiology · 2019Review
- T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.International review of cell and molecular biology · 2019Review
- Five Residues in the Apical Loop of the Respiratory Syncytial Virus Fusion Protein FJournal of virology · 2018Article
- Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem.Journal of virology · 2018Review
- Novel recombinant DNA vaccine candidates for human respiratory syncytial virus: Preclinical evaluation of immunogenicity and protection efficiency.Human vaccines & immunotherapeutics · 2017Article
- Modulation of the host immune response by respiratory syncytial virus proteins.Journal of microbiology (Seoul, Korea) · 2017Review
- Current Landscape of Antiviral Drug Discovery.F1000Research · 2016Review
- Atomic force microscopic investigation of respiratory syncytial virus infection in HEp-2 cells.Journal of microscopy · 2014Article
- Lamb model of respiratory syncytial virus-associated lung disease: insights to pathogenesis and novel treatments.ILAR journal · 2014Review
- Advances in antivirals for non-influenza respiratory virus infections.Influenza and other respiratory viruses · 2013Review
- Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus.Advances in virology · 2013Review
- Structure and function of respiratory syncytial virus surface glycoproteins.Current topics in microbiology and immunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Respiratory syncytial virus (RSV) is the most significant cause of pediatric respiratory infections. Palivizumab (Synagis®), a humanized monoclonal antibody, has been used successfully for a number of years to prevent severe RSV disease in at-risk infants. However, despite intense efforts, there is no approved vaccine or small molecule drug for RSV. As an enveloped virus, RSV must fuse its envelope with the host cell membrane, which is accomplished through the actions of the fusion (F) glycoprotein, with attachment help from the G glycoprotein. Because of their integral role in initiation of infection and their accessibility outside the lipid bilayer, these proteins have been popular targets in the discovery and development of antiviral compounds and vaccines against RSV. This review examines advances in the development of antiviral compounds and vaccine candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.